8-K: Enzon Stockholders Approve Merger, 1-for-100 Reverse Split

Enzon Pharmaceuticals, Inc. stockholders have approved a 1-for-100 reverse stock split and the merger agreement with Viskase Companies, Inc.

Summary

• Stockholders of Enzon Pharmaceuticals, Inc. (Enzon) have approved a 1-for-100 reverse stock split of the company's common stock.
• Stockholders also approved the Agreement and Plan of Merger with Viskase Companies, Inc. and EPSC Acquisition Corp., as amended.
• The Reverse Stock Split Proposal was approved by 40,993,338 shares, representing 55.2% of the issued and outstanding Enzon Common Stock.
• The Merger Proposal was approved by 42,350,448 shares, representing 57.1% of the issued and outstanding Enzon Common Stock.
• The requisite number of consents was received as of 8:00 a.m., Eastern Time, on February 11, 2026, concluding the consent solicitation period.
• As of the Record Date, January 29, 2026, there were 74,214,603 shares of Enzon Common Stock outstanding and entitled to vote.
• The closing of the merger transactions remains subject to the satisfaction or waiver of remaining conditions outlined in the Merger Agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company successfully secured stockholder approval for key strategic initiatives (merger and reverse split), removing significant uncertainties. However, the necessity of a 1-for-100 reverse split introduces a cautionary element regarding the company's prior market valuation.

Positives

• Stockholders have provided the necessary approvals for both the reverse stock split and the merger with Viskase Companies, Inc., indicating support for the company's strategic direction.
• The successful conclusion of the consent solicitation removes a key hurdle for the proposed merger and corporate restructuring.

Negatives

• A 1-for-100 reverse stock split often indicates a significantly low share price, which can be perceived negatively by the market and may be a measure to meet exchange listing requirements or improve market perception rather than a sign of strong underlying performance.

Risks

• The risk that conditions to the closing of the proposed transaction are not satisfied, including failure to obtain necessary approvals.
• Uncertainties regarding the timing of the consummation of the proposed transaction and the ability of Enzon and Viskase to complete it.
• The ability of Viskase to timely deliver financial statements required by the Merger Agreement.
• The possibility that anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, growth, and tax treatment, may not be realized.
• Potential litigation related to the proposed transaction against Enzon, Viskase, or their officers/directors.
• Possible disruptions from the proposed transaction that could harm Enzon's or Viskase's respective businesses.
• The ability of Viskase to retain, attract, and hire key personnel.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties resulting from the announcement or completion of the proposed transaction.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Enzon's or Viskase's ability to pursue business opportunities or strategic transactions.
• Uncertainty regarding the exchange ratio and relative ownership levels at the closing of the merger.
• Estimates regarding future revenue, expenses, and capital requirements following the merger closing.
• Legislative, regulatory, and economic developments.
• Unpredictability and severity of catastrophic events, including acts of terrorism, trade wars, or outbreak of war or hostilities.

Future Outlook

The company anticipates proceeding with the closing of the transactions contemplated by the Merger Agreement, subject to the satisfaction or waiver of remaining conditions. The combined company's common stock is expected to be quoted on the OTCQB tier of the OTC market of the OTC Markets Group, Inc.

Management Comments

• Richard L. Feinstein, Chief Executive Officer, Chief Financial Officer, and Secretary, signed the report on behalf of Enzon Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that this announcement reflects a strategic move by Enzon Pharmaceuticals to merge with Viskase Companies, Inc., a company primarily involved in food packaging. This indicates a significant pivot or diversification for Enzon, moving away from its traditional pharmaceutical focus. The approval of a 1-for-100 reverse stock split is a common tactic for companies with low share prices, often aimed at meeting exchange listing requirements or making the stock more attractive to institutional investors, though it doesn't change the company's market capitalization. The merger itself represents a consolidation play, potentially seeking synergies or a new strategic direction for the combined entity.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase, or their respective officers or directors is listed as a risk factor.

Stakeholder Impact

• Shareholders: Will experience a 1-for-100 reverse stock split and become shareholders in the combined Enzon-Viskase entity, subject to the merger's completion.
• Employees: Viskase's ability to retain, attract, and hire key personnel is identified as a risk, suggesting potential impact on employee stability and morale.
• Customers and Suppliers: Potential adverse reactions or changes to relationships with customers and suppliers are identified as risks due to the merger announcement or completion.

Next Steps

• Proceed with the closing of the transactions contemplated by the Merger Agreement.
• Satisfy or waive the remaining conditions to closing set forth in the Merger Agreement.

Key Dates

Recommendation

The approval of the merger and reverse stock split represents significant corporate actions that could reshape the company's future. While the approvals are a positive step towards executing the strategy, the merger is still subject to closing conditions, and the reverse split often signals underlying challenges. Investors should hold to observe the successful completion of the merger, the integration process, and the performance of the combined entity before making further investment decisions.

Keywords

Enzon Pharmaceuticals, Viskase Companies, Merger Agreement, Reverse Stock Split, Stockholder Approval, Corporate Action, SEC Filing, Pharmaceuticals, Food Packaging